Endovascular therapy for acute ischemic stroke is indicated and evidence based: A position statement

Journal of NeuroInterventional Surgery

Volumn 7, Issue 2, 2015, Pages 79-81

  Mocco, J ^a   Fiorella, David ^c   Fargen, Kyle M ^b   Albuquerque, Felipe ^d   Chen, Michael ^e   Gupta, Rishi ^f   Hirsch, Joshua A ^k   Linfante, Italo ^g   Mack, William ^h   Rai, Ansaar T ⁱ   Tarr, Robert W ^j  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BAPTIST CARDIAC AND VASCULAR INSTITUTE   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ WEST VIRGINIA UNIVERSITY HOSPITALS   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DESMOTEPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; BRAIN ISCHEMIA; DRUG MEGADOSE; ENDOVASCULAR THERAPY; EVIDENCE BASED PRACTICE; HUMAN; INTRAARTERIAL THROMBOLYSIS; LARGE VESSEL OCCLUSION; LOW DRUG DOSE; MECHANICAL THROMBECTOMY; MEDICAL ETHICS; NONSURGICAL INVASIVE THERAPY; NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECANALIZATION; THROMBECTOMY DEVICE; TREATMENT INDICATION; TREATMENT OUTCOME; ENDOVASCULAR SURGERY; EVIDENCE BASED MEDICINE; MULTICENTER STUDY (TOPIC); PROCEDURES; STROKE; TRENDS;

BRAIN ISCHEMIA; ENDOVASCULAR PROCEDURES; EVIDENCE-BASED MEDICINE; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84920982991     PISSN: 17598478     EISSN: 17598486     Source Type: Journal    
DOI: 10.1136/neurintsurg-2014-011591     Document Type: Note

References (22)

1. Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368: 893-903.
2. Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368: 914-23.
3. Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368: 904-13.
4. Dippel D, Berkhemer O, Fransen P, et al. Results of the multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands. Paper Presented at: 9th World Stroke Conference; 25 October 2014; Istanbul, Turkey.
5. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial. Lancet 2012;380: 1231-40.
6. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet 2012;380: 1241-9.
7. Albuquerque FC, Fiorella D, Hirsch JA, et al. The tribulations of stroke trials. J Neurointerv Surg 2013;5: 181-3.
8. Khalessi AA, Fargen KM, Lavine S, et al. Commentary: Societal statement on recent acute stroke intervention trials: Results and implications. Neurosurgery 2013;73: E375-9.
9. Broderick JP, Palesch YY, Demchuk AM, et al. Evolution of practice during the Interventional Management of Stroke III trial and implications for ongoing trials. Stroke 2014;45: 3606-11.
10. Fargen KM, Neal D, Fiorella DJ, et al. A metaanalysis of prospective randomized controlled trials evaluating endovascular therapy for acute ischemic stroke. J Neurointerv Surg 2015;7: 85-90.
11. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological disorders and stroke rt-PA stroke study group. N Engl J Med 1995;333: 1581-7.
12. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274: 1017-25.
13. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352: 1245-51.
14. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282: 2019-26.
15. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359: 1317-29.
16. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre acute stroke trial-Italy (MAST-I) Group. Lancet 1995;346: 1509-14.
17. Thrombolytic therapy with streptokinase in acute ischemic stroke. The multicenter acute stroke trial- Europe Study Group. N Engl J Med 1996;335: 145-50.
18. Donnan GA, Davis SM, Chambers BR, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group. JAMA 1996;276: 961-6.
19. Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebocontrolled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000;31: 811-6.
20. Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomised trial. Lancet Neurol 2008;7: 299-309.
21. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8: 141-50.
22. Sandercock P, Wardlaw JM, Lindley RI, et al; IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): A randomised controlled trial. Lancet 2012;379: 2352-63.